Literature DB >> 16783258

[Acute respiratory failure and septic shock induced by Mycobacterium bovis. A rare side effect of intravesical BCG therapy].

Gilles Rival1, Denis Garot, Emmanuelle Mercier, Bérangère Narciso, Annick Legras, Dominique Perrotin, Pierre-François Dequin.   

Abstract

INTRODUCTION: Intravesical bacillus Calmette-Guerin (BCG) therapy, recommended for superficial bladder tumors, triggers side effects in fewer than 5% of patients. The most severe side effects, however, are septic shock and acute respiratory failure. CASE: A 70-year-old man was hospitalized for septic shock with acute respiratory and renal failure after intravesical instillation of BCG, which was identified in the gastric aspiration sample. Treatment with rifampicin, ethambutol, isoniazid, and corticosteroid therapy, as well as standard reanimation measures, led to the patient's recovery. DISCUSSION: This case shows the potentially severe side effects of intravesical BCG instillation. Although this treatment is well tolerated in more than 95% of patients and its systemic complications can be effectively treated, these side effects can be life-threatening.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16783258     DOI: 10.1016/s0755-4982(06)74732-7

Source DB:  PubMed          Journal:  Presse Med        ISSN: 0755-4982            Impact factor:   1.228


  7 in total

1.  Concurrent granulomatous hepatitis, pneumonitis and sepsis as a complication of intravesical BCG immunotherapy.

Authors:  Vasiliki Delimpoura; Konstantinos Samitas; Ioannis Vamvakaris; Eleftherios Zervas; Mina Gaga
Journal:  BMJ Case Rep       Date:  2013-10-10

2.  Disseminated Mycobacterium bovis Infection Complicating Intravesical BCG Instillation for the Treatment of Superficial Transitional Cell Carcinoma of the Bladder.

Authors:  Fatehi Elzein; Nada Albogami; Mustafa Saad; Nazik El Tayeb; Abdullah Alghamdi; Ghaleb Elyamany
Journal:  Clin Med Insights Case Rep       Date:  2016-08-16

Review 3.  Bacillus Calmette-Guérin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature.

Authors:  María Asunción Pérez-Jacoiste Asín; Mario Fernández-Ruiz; Francisco López-Medrano; Carlos Lumbreras; Ángel Tejido; Rafael San Juan; Ana Arrebola-Pajares; Manuel Lizasoain; Santiago Prieto; José María Aguado
Journal:  Medicine (Baltimore)       Date:  2014-10       Impact factor: 1.889

4.  Favorable Outcome in a Patient with Systemic BCGitis After Intra-bladder Instillation of Calmette-Guerin Bacillus Highlighting the Importance of Making the Correct Diagnosis in this Rare Form of Sepsis.

Authors:  Rachid Attou; Thomas Albrich; Joe Kadou; Sebastien Redant; Patrick M Honoré; David De Bels
Journal:  J Transl Int Med       Date:  2019-03-29

5.  Peritoneal tuberculosis and granulomatous hepatitis secondary to treatment of bladder cancer with Bacillus Calmette-Guérin.

Authors:  Aliye Soylu; Ali T Ince; Hakan Polat; Nurgul Yasar; Aydin Ciltas; Selvinaz Ozkara; Ali I Tasci
Journal:  Ann Clin Microbiol Antimicrob       Date:  2009-04-15       Impact factor: 3.944

6.  Systemic BCG-Osis as a Rare Side Effect of Intravesical BCG Treatment for Superficial Bladder Cancer.

Authors:  S Lukacs; B Tschobotko; N A Szabo; Andrew Symes
Journal:  Case Rep Urol       Date:  2013-06-17

7.  Mycobacterium bovis Osteomyelitis of the Thoracic Spine Mimicking a Metastatic Lytic Lesion in a Patient Exposed to Intravesicular Bacille Calmette-Guérin Treatment.

Authors:  Jessica R Newman; Lisa A Clough; Fernando Merino
Journal:  Urol Case Rep       Date:  2014-07-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.